Alliancebernstein L.P. Nurix Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$290 Billion
Q2 2025

A detailed history of Alliancebernstein L.P. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 63,320 shares of NRIX stock, worth $779,469. This represents 0.0% of its overall portfolio holdings.

Number of Shares

63,320

Previous 63,320 -0.0%

Holding current value

$779,469

Previous $752,000 4.12%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $202,657 - $359,118	16,860 Added 36.29%	63,320 $1.32 Million
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $589,500 - $756,000	-75,000 Reduced 61.75%	46,460 $365,000
Q2 2023 Aug 15, 2023	BUY	$8.7 - $13.28 $740,891 - $1.13 Million	85,160 Added 234.6%	121,460 $1.21 Million
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $1.08 Million - $1.68 Million	-126,600 Reduced 77.72%	36,300 $322,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $788,800 - $1.17 Million	80,000 Added 96.5%	162,900 $1.79 Million
Q3 2022 Nov 15, 2022	BUY	$12.33 - $19.81 $118,848 - $190,948	9,639 Added 13.16%	82,900 $1.08 Million
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $318,044 - $598,150	40,361 Added 122.68%	73,261 $928,000
Q1 2022 May 13, 2022	BUY	$12.94 - $29.65 $1,294 - $2,965	100 Added 0.3%	32,900 $461,000
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $1.58 Million - $2.06 Million	-59,724 Reduced 64.55%	32,800 $950,000
Q3 2021 Nov 10, 2021	BUY	$22.71 - $36.69 $1.36 Million - $2.19 Million	59,724 Added 182.09%	92,524 $2.77 Million
Q2 2021 Jul 30, 2021	BUY	$24.21 - $35.89 $794,088 - $1.18 Million	32,800 New	32,800 $870,000

Others Institutions Holding NRIX

# of Institutions

174

Shares Held

79.5M

Call Options Held

126K

Put Options Held

11.3K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $580M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Nurix Therapeutics, Inc. Transaction History